



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/574,917	04/11/2006	Yipu Feng	13695/1	5543
26646	7590	02/18/2010	EXAMINER	
KENYON & KENYON LLP			KWON, BRIAN YONG S	
ONE BROADWAY				
NEW YORK, NY 10004			ART UNIT	PAPER NUMBER
			1614	
			MAIL DATE	DELIVERY MODE
			02/18/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/574,917	FENG ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Brian-Yong S. Kwon	1614	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

1) Responsive to communication(s) filed on 22 December 2009.  
 2a) This action is FINAL.                    2b) This action is non-final.  
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

4) Claim(s) 6-8 is/are pending in the application.  
 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.  
 5) Claim(s) \_\_\_\_\_ is/are allowed.  
 6) Claim(s) 6-8 is/are rejected.  
 7) Claim(s) \_\_\_\_\_ is/are objected to.  
 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

9) The specification is objected to by the Examiner.  
 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
     Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
     Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
 a) All    b) Some \* c) None of:  
 1.) Certified copies of the priority documents have been received.  
 2.) Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3.) Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____ .
3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)	5) <input type="checkbox"/> Notice of Informal Patent Application
Paper No(s)/Mail Date <u>02/09/10</u> .	6) <input type="checkbox"/> Other: _____ .

***Status of Application***

1. Acknowledgement is made of applicants' filing of the instant application as a Request for Continued Examination (RCE) under 37 CFR 1.1114.
2. Acknowledgement is made of applicant's remarks filed on 12/22/2009.
3. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set of actions being applied to the instant application.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any

evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

4. Claims 6-8 are rejected under 35 U.S.C. 103(a) as being unpatentable over. Chang et al. (Acta Pharmacologica Sinica, August 2003, 24(8), pp. 796-804), and further in view of Lee et al. (US 6716822) and Izozumi et al. (Tokai J Exp Clin Med., vol. 23, No. 3, pp. 103-117, 1998).

Chang teaches use of 3-n-butylphthalide, preferably 1-3-butylphthalide (NBP) as effective agent for improving ischemia-induced apoptosis, particularly transient focal cerebral ischemia-apoptosis (abstract; materials and methods; discussion, especially para. 3 of page 803), wherein said compound is administered in dosage amounts in range from 5mg-20mg/kg to a subject after the ischemia (Figures). Chang discloses that “neuronal cell loss after cerebral ischemia involved apoptosis...the apoptotic process largely contributed to the expansion of the ischemic damage”; “antiapoptotic maneuvers could reduce neuronal death and infarct volume”; and that the beneficial effects NBP on cerebral ischemia-induced apoptosis, by inhibiting apoptosis, might be useful for the treatment of ischemic cerebrovascular diseases (page 797, column 1, para. 1; page 803, column 1, last paragraph).

Lee is being provided as a supplemental reference to demonstrate the state of the art knowledge in using apoptosis-inhibiting agent for the treatment of cerebral infarction (abstract).

Izozumi is being provided as a supplemental reference to demonstrate the state of the art knowledge in using focal cerebral ischemia model as an experimental model of cerebral infarction (page 106, column 1, para. 3 through page 108, column 1, para. 1).

The teaching of Chang differs from the claimed invention in the use of said NBP in the therapeutic treatment of cerebral infarction. To incorporate such teaching into the teaching Chang, would have been obvious in view of Lee who teaches or suggest the utility of antiapoptotic agent for the treatment of (cerebral infarct) stroke and Izozumi who teaches the focal cerebral ischemia animal model as a well recognized experimental model of cerebral infarction.

One having ordinary skill in the art would have expected that there is nexus between neuronal apoptosis and cerebral infarction or stroke. Thus, one having ordinary skill in the art would have been motivated to modify the Chang, with the reasonable expectation of success, to arrive at the instant invention.

As evidenced by Izozumi, one having ordinary skill in the art has basis for perceiving those studies provided in Chang as constituting recognized procedure with clear relevance to therapeutic utility in treating cerebral infarction, in animals or humans.

The prior art does not disclose the underlying pharmacological mechanism of “to reduce the volume of the cerebral infarction”. However, the fact that the applicant may have discovered a new pharmacological mechanism for L-butylphthalide of formula (I) is not considered patentably distinctive over the prior art which are directed to the same therapeutic application (for the treatment of cerebral infarct induced by focal cerebral ischemia). The examiner considers that such property deems to be a necessary consequence of what is deliberately intended in the prior art method. . Thus, the references in combination make obvious the instant invention.

Applicant has presented no evidence to establish the unexpected or unobvious nature of the claimed invention, and as such, claims 608 are properly rejected under 35 U.S.C. 103.

***Response to Arguments***

5. Applicant's arguments filed 06/16/2009 have been fully considered but they are not persuasive.

Applicant's argument in the response takes the position that the disclosure that l-butylphthalide might have important implications for the treatment of ischemic cerebrovascular disease is not the same as disclosing "that the beneficial effects NBP on cerebral ischemia-induced apoptosis might be useful for the treatment of ischemic cerebrovascular diseases" because it is not clear Chang meant with the term "important implications".

This is spurious argument. It is generally recognized that animal models of middle cerebral artery occlusion or blockade are widely used for the study of stroke or focal ischemia because they closely mimic the effects of stroke or focal ischemia in man (see US 5914112, US 20030219430, US 5733524, US 6350739 and US 5744500). Thus, one having ordinary skill in the art has basis for perceiving those studies provided in Chang as constituting recognized procedure with clear relevance to therapeutic utility in treating cerebral infarction, in animals or humans.

Applicant's argument in the response takes the position that there is no clear relationship between the inhibition of apoptosis caused by l-butylphthalide and the treatment of cerebral infarct. Furthermore, applicant alleges that there is no clear relationship between the inhibition of apoptosis caused by l-butylphthalide and the reduction of the volume of cerebral infarct. Applicant argues that the relationship of neuronal apoptosis and infarct size is complicated such

Art Unit: 1614

that a person of ordinary skill in the art would not have reasonable expectation at the time of the invention was made that l-butylphthalide would reduce the volume of the cerebral infarct.

This argument is not found persuasive. Unlike the applicant's argument, the nexus between the neuronal apoptosis and the cerebral infarction or stroke was well known at the time of the invention was made as discussed above in US'822 (see also USP 6399576, USP 6106830, and USP 2002/0025985). Thus, one having ordinary skill in the art would have been motivated to modify the Chang, with the reasonable expectation of success, to arrive at the instant invention.

### Conclusion

6. No Claim is allowed.

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Kwon whose telephone number is (571) 272-0581. The examiner can normally be reached Tuesday through Friday from 9:00 am to 7:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel, can be reached on (571) 272-0718. The fax number for this Group is (571) 273-8300.

Any inquiry of a general nature of relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

Art Unit: 1614

applications may be obtained from Private PAIR only. For more information about PAIR system, see <http://pair-direct.uspto.gov> Should you have any questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll free).

/Brian-Yong S Kwon/  
Primary Examiner, Art Unit 1614